Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
9.72
+0.47 (5.08%)
At close: Mar 31, 2026, 4:00 PM EDT
9.73
+0.01 (0.10%)
Pre-market: Apr 1, 2026, 5:19 AM EDT
Prothena Corporation Revenue
In the year 2025, Prothena Corporation had annual revenue of $9.68M, down -92.83%. Prothena Corporation had revenue of $21.00K in the quarter ending December 31, 2025, a decrease of -99.01%.
Revenue (ttm)
$9.68M
Revenue Growth
-92.83%
P/S Ratio
54.03
Revenue / Employee
$144,537
Employees
67
Market Cap
523.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | -125.47M | -92.83% |
| Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
| Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
| Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
| Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
| Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
| Dec 31, 2019 | 814.00K | -141.00K | -14.76% |
| Dec 31, 2018 | 955.00K | -26.56M | -96.53% |
| Dec 31, 2017 | 27.52M | 26.46M | 2,508.44% |
| Dec 31, 2016 | 1.06M | -552.00K | -34.35% |
| Dec 31, 2015 | 1.61M | -49.25M | -96.84% |
| Dec 31, 2014 | 50.85M | 50.18M | 7,422.78% |
| Dec 31, 2013 | 676.00K | -1.98M | -74.57% |
| Dec 31, 2012 | 2.66M | 2.15M | 424.26% |
| Dec 31, 2011 | 507.00K | -736.00K | -59.21% |
| Dec 31, 2010 | 1.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Zevra Therapeutics | 106.47M |
| Fulcrum Therapeutics | 80.00M |
| Aclaris Therapeutics | 7.83M |
| ProKidney | 893.00K |
| YD Bio | 510.36K |
| vTv Therapeutics | 17.00K |
PRTA News
- 10 days ago - Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026 - Business Wire
- 22 days ago - Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 4 weeks ago - Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution - Seeking Alpha
- 4 weeks ago - Prothena Announces up to $100 Million Share Repurchase Plan - Business Wire
- 5 weeks ago - Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire
- 6 weeks ago - Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
- 3 months ago - Prothena Announces Board of Directors Update - Business Wire